Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06713447




Registration number
NCT06713447
Ethics application status
Date submitted
26/11/2024
Date registered
3/12/2024
Date last updated
3/12/2024

Titles & IDs
Public title
NTI164 Human PK Study
Scientific title
A Pharmacokinetic Study of NTI164 in Healthy Adult Volunteers
Secondary ID [1] 0 0
FENPK1
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Healthy 0 0
Healthy Volunteer 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - NTI164

Experimental: NTI164 active - All participants will be in this arm (single intervention) and will receive NTI164.


Treatment: Drugs: NTI164
This intervention uses Full-Spectrum Medicinal Cannabis Plant Extract with a low THC concentration of 0.08% (NTI164) specifically formulated to target inflammation in various neurological conditions. The dose of 20mg/kg has been selected based off existing clinical trial evidence for NTI164, and is similar to the dose of other cannabis-based drugs used in neurology. The safety of NTI164 has been rigorously tested in several ongoing paediatric clinical trials through blood tests and clinician-rated surveys.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Peak plasma concentration (Cmax)
Timepoint [1] 0 0
Up to 21 days
Secondary outcome [1] 0 0
Ae t1-t2 - urine
Timepoint [1] 0 0
Up to 21 days

Eligibility
Key inclusion criteria
1. Must have given written informed consent before any study-related activities are performed and must be able to understand the full nature and purpose of the study, including possible risks and AEs.
2. Adult males and females, 18 to 65 years of age (inclusive) at screening.
3. BMI = 18.0 and = 32.0 kg/m2, with a body weight of at least 50 kg.
4. Medically healthy (in the opinion of the Investigator), as determined by pre-study medical history and without clinically significant abnormalities. Must have:

1. Physical examination without any clinically relevant findings;
2. Systolic blood pressure (BP) in the range of 90 to 145 mmHg and diastolic BP in the range of 50 to 95 mmHg after resting for 5 minutes in a supine position.
3. Pulse rate in the range of 45 to 100 bpm after 5 minutes resting in a supine position.
4. Body temperature (tympanic), between 35.5°C and 37.7°C.
5. Electrocardiogram (ECG) without clinically significant abnormalities including QT interval corrected for Fredericia (QTcF) <450 msec, QRS interval < 120 msec and PR interval < 220 msec, based on the average of triplicate measurements.
6. No clinically significant findings in serum chemistry, haematology, coagulation, and urinalysis tests.
5. Female participants:

1. Must be of non-child-bearing potential, i.e., surgically sterilised (hysterectomy, bilateral salpingectomy, bilateral oophorectomy) at least 6 weeks before the screening visit or postmenopausal (with postmenopausal defined as no menses for 12 months without an alternative medical cause and a follicle-stimulating hormone (FSH) level consistent with postmenopausal status, per local laboratory guidelines), or
2. If of child-bearing potential, must:

i. Have a negative pregnancy test at the screening visit and on admission to the study site on Day-1. ii. Agree not to attempt to become pregnant or donate ova from signing the consent form until at least 30 days after the last dose of study drug. iii. Agree to use adequate contraception (defined as use of a condom by the male partner combined with use of a highly effective method of contraception (e.g. hormonal contraception, intrauterine device, bilateral tube occlusion, etc.) from one month prior to screening until at least 30 days after the last dose of study drug, if not exclusively in a same-sex relationship or abstinent as a committed lifestyle.
6. Male participants:

1. Must agree not to donate sperm from signing the consent form until at least 90 days after the last dose of study drug.
2. If engaging in sexual intercourse with a female partner who could become pregnant, agree to use adequate contraception (defined as use of a condom combined with use of a highly effective female method of contraception (as above)) from signing the consent form until at least 90 days after the last dose of study drug.
3. If engaging in sexual intercourse with a female partner who is not of childbearing potential or a same-sex partner, agree to use a condom from signing the consent form until at least 90 days after the last dose of study drug.
4. Practise true abstinence: when this is in line with their preferred and usual lifestyle.
7. Have suitable venous access for blood sampling.
8. Abstain from alcohol for the duration of the study period.
9. Be willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions.
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
1. Known hypersensitivity to any of the study drug ingredients.
2. History of anaphylaxis or other significant allergy (including system sensitivity to any aerosol) which, in the opinion of the Investigator, would interfere with the participant's ability to participate in the study.
3. History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, haematological, gastrointestinal, endocrine, immunologic, dermatologic, psychiatric, or neurological disease/disorder, including any acute illness, determined by the Investigator to be clinically relevant.
4. Current diagnosis of bipolar disorder, major depressive disorder, psychosis, schizophrenia, or schizoaffective disorder.
5. History of major surgery or hospitalisation within 12 weeks prior to screening, or surgery planned during the study.
6. History of malignant disease in the last 10 years (excludes surgically resected skin squamous cell or basal cell carcinoma).
7. Clinically relevant history or presence of rhythm disorders (e.g. sinoatrial heart block, second- or third-degree atrioventricular block, long QT syndrome, symptomatic bradycardia, atrial flutter, or atrial fibrillation), clinically-relevant history of hypokalaemia, congestive heart failure, or structural heart disease.
8. Presence or having sequelae of gastrointestinal, liver (with the exception of Gilbert's syndrome), kidney, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
9. Serum or plasma potassium <3.5 or >5.2 mmol/L, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 1.5 x upper limit of normal (ULN), or total bilirubin >2 x ULN at screening or Day -1 (except for Gilbert's syndrome).
10. History of or positive test results for HIV, HBsAg, or HCV antibodies at screening.
11. Positive drugs of abuse test, urine cotinine test, and/or urine alcohol test results at screening and/or on admission to the clinical facility on Day -1.
12. History or clinical evidence of alcoholism or drug abuse (in the opinion of the Investigator) within the 3-year period prior to screening.
13. Regular consumption of >10 standard alcoholic beverages/week, where 1 standard drink is 10g of pure alcohol and is equivalent to 285 mL beer (4.9% Alc/Vol), 100 mL wine (12% Alc/Vol), or 30mL spirit (40% Alc/Vol).
14. Excessive caffeine consumption, defined as = 800 mg per day at screening (1 cup of coffee contains ~100 mg caffeine, 1 cup of tea or one glass of cola contains ~40 mg caffeine, 1 can of Red Bull contains ~80 mg caffeine).
15. Females who are pregnant, breastfeeding, or planning to breastfeed.
16. Use of any prescribed medications (including vaccines) or over-the-counter medications (including herbal medicines, such as St John's Wort, homeopathic preparations, dietary supplements, vitamins, and minerals) within 2 weeks (or 5 half-lives, whichever is longer) prior to (first) study treatment administration, except the use of contraceptives, and occasional use of paracetamol and/or ibuprofen (at the discretion of the Investigator).
17. Received any vaccinations within 14 days prior to screening.
18. Donation of blood or plasma within 12 weeks prior to screening, loss of whole blood of >500mL within 12 weeks prior to first dose of study drug, or receipt of a blood transfusion within 1 year of first dose of study drug.
19. Participation in another clinical study of an investigational drug or device within 12 weeks prior to screening.
20. Any other condition or prior therapy that, in the opinion of the Investigator, would make the participant unsuitable for this study, including inability to cooperate fully with the requirements of the study protocol or likelihood of noncompliance with any study requirements.
21. Currently using or has used recreational or medicinal cannabis or cannabinoid-based medications within the 12 weeks prior to screening and is unwilling to abstain for the duration of the study.
22. Had brain surgery or a traumatic brain injury within 1 year of screening.
23. History of suicidal behaviour or suicidal ideation of type 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) in the 12 weeks prior to screening and in ongoing assessment throughout the study.
24. Has previously been enrolled in this study.

Study design
Purpose of the study
Other
Allocation to intervention
Not applicable
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
1/12/2024
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/06/2025
Actual
Sample size
Target
12
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA
Recruitment hospital [1] 0 0
CMAX Clinical Research Pty Ltd - Adelaide
Recruitment postcode(s) [1] 0 0
5000 - Adelaide

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Fenix Innovation Group
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
CMAX Clinical Research Pty Ltd
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Other
Name [2] 0 0
Neurotech International
Address [2] 0 0
Country [2] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Richard Newman, MBBS
Address 0 0
Country 0 0
Phone 0 0
+618 7088 7900
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries

Data sharing statement


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT06713447